Overall, while DPP-4 inhibitors are generally considered neutral for atherosclerotic CV outcomes, caution is warranted in prescribing saxagliptin - and potentially alogliptin - particularly in patients with pre-existing heart failure or at high risk of developing it. Here, DPP4 is linked to heart failure.